Clinical and genetic risk factors define two risk groups of extracranial malignant rhabdoid tumours (eMRT/RTK)
- 1 January 2021
- journal article
- research article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 142, 112-122
- https://doi.org/10.1016/j.ejca.2020.10.004
Abstract
No abstract availableKeywords
Funding Information
- Deutsche Forschungsgemeinschaft (DFG FR 1516/4-1)
- Fördergemeinschaft Kinderkrebs-Zentrum Hamburg
- Deutsche Kinderkrebsstiftung (DKKS A2016/34 04.2014)
This publication has 31 references indexed in Scilit:
- Favorable outcome of patients affected by rhabdoid tumors due to rhabdoid tumor predisposition syndrome (RTPS)Pediatric Blood & Cancer, 2013
- Extracranial rhabdoid tumours: what we have learned so far and future directionsThe Lancet Oncology, 2013
- Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumorsPediatric Blood & Cancer, 2012
- Epidemiology of rhabdoid tumors of early childhoodPediatric Blood & Cancer, 2012
- Malignant rhabdoid tumours of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: A report of the SIOP renal tumour study groupPediatric Blood & Cancer, 2010
- Germline Nonsense Mutation and Somatic Inactivation of SMARCA4/BRG1 in a Family with Rhabdoid Tumor Predisposition SyndromeAmerican Journal of Human Genetics, 2010
- Clinical and molecular features in patients with atypical teratoid rhabdoid tumor or malignant rhabdoid tumorGenes, Chromosomes and Cancer, 2009
- Age, stage, and radiotherapy, but not primary tumor site, affects the outcome of patients with malignant rhabdoid tumorsPediatric Blood & Cancer, 2009
- The 2007 WHO classification of tumours of the central nervous systemActa Neuropathologica, 2007
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007